PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Cited by 10 Publications

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.
Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.
Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	NIj5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjnTWM2OD1yLkiyNFI1KM7:TR?=	Ml:yV2FPT0WU
UACC-893	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nZTWlEPTB;NT6xPVg5PiEQvF2=	NXLl[4VEW0GQR1XS
A427	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnuOIJKSzVyPUWuO\|I2PjdizszN	MUTTRW5ITVJ?
OCUB-M	M3e1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTwTpVtUUN3ME22MlY3OTB{IN88US=>	NX;IUJBiW0GQR1XS
SW684	NVS1OHRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPGVGFKSzVyPUeuOVIzPjhizszN	MXnTRW5ITVJ?
SK-LMS-1	NGnsN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPITWM2OD17LkCxN\|AzKM7:TR?=	MY\TRW5ITVJ?
CP50-MEL-B	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHX2c3JKSzVyPUmuN\|A1OTlizszN	MXPTRW5ITVJ?
NCI-H1651	M3HCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PMRWlEPTB;MUCuNFI4PiEQvF2=	M2\2WnNCVkeHUh?=
ABC-1	NETZVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDZTWM2OD1zMD6xNFM4KM7:TR?=	NXOwb3V5W0GQR1XS
OE19	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPSTWM2OD1zMD6xO\|M{KM7:TR?=	MoDGV2FPT0WU
DSH1	NVvFRpNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2frUmlEPTB;MUCuPFg4QSEQvF2=	M1WzU3NCVkeHUh?=
SW13	M33uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFzLkmzNVkh\|ryP	M1HvV3NCVkeHUh?=
MDA-MB-453	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1ywUWlEPTB;MUKuNVYxOyEQvF2=	NX21W\|Z2W0GQR1XS
647-V	NVjYfVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{W3eGlEPTB;MUKuN\|U5OiEQvF2=	NUTCV\|NtW0GQR1XS
NCI-H2342	NV;wTGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL5[2tiUUN3ME2xNk4{QTl3IN88US=>	NFT5WFNUSU6JRWK=
LB2241-RCC	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\nfmlEPTB;MUKuOVc4QSEQvF2=	NVfjUZoxW0GQR1XS
UACC-257	NIjOSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;XZWlEPTB;MUOuOFQ2OyEQvF2=	MUDTRW5ITVJ?
NCI-H661	NG[zR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu3dpZKSzVyPUGzMlY1PDlizszN	MnvYV2FPT0WU
FADU	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC2fI5VUUN3ME2xN{43QTl{IN88US=>	NUjx[I5mW0GQR1XS
A2780	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\UepRiUUN3ME2xN{45ODRzIN88US=>	MVrTRW5ITVJ?
NCI-H1793	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\6PGlEPTB;MUSuOFA5PSEQvF2=	MWTTRW5ITVJ?
TE-8	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j2dGlEPTB;MUWuN\|Q3PSEQvF2=	NYjw[WRnW0GQR1XS
HGC-27	NFzScnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;ESWlEPTB;MU[uNVY1PCEQvF2=	M2rBPXNCVkeHUh?=
MMAC-SF	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTF5LkO3Nlch\|ryP	NUXBXJVzW0GQR1XS
Calu-6	NWrNbFg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe0Tlk6UUN3ME2xPE4yPTF\|IN88US=>	MYHTRW5ITVJ?
HUTU-80	M4K5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInRTYlKSzVyPUG4MlM6PTlizszN	NWLs[GxuW0GQR1XS
SAS	NFrhVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTF6Lk[0OVUh\|ryP	NXyxW2VDW0GQR1XS
IST-MES1	NUC4RY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXWTWM2OD1zOD62OVA5KM7:TR?=	MlLuV2FPT0WU
C3A	NH6wPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTHcFZKSzVyPUG4Mlc6OTlizszN	MlzKV2FPT0WU
ES3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvlUXVKSzVyPUG4Mlg{PjRizszN	NHO5PYxUSU6JRWK=
HSC-2	NXfGRop[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jNRmlEPTB;MUmuOlU1OSEQvF2=	NIHQWpZUSU6JRWK=
T47D	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXRbYltUUN3ME2yNE4yPDh3IN88US=>	NUKxPHJLW0GQR1XS
EW-7	NWDtelRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M362W2lEPTB;MkCuPFU5QCEQvF2=	M3viVnNCVkeHUh?=
LN-405	M2PaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TnPGlEPTB;MkCuPFk3PSEQvF2=	MU\TRW5ITVJ?
U031	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlflTWM2OD1{MT60PFAzKM7:TR?=	MkDpV2FPT0WU
A549	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPLdGtzUUN3ME2yNU45PDlzIN88US=>	MWPTRW5ITVJ?
RMG-I	M{LHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfCTWM2OD1{Mj6yOlY5KM7:TR?=	M2jQZ3NCVkeHUh?=
BT-474	M3O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ{Lk[1OVEh\|ryP	NHLOeGRUSU6JRWK=
NB69	M1PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJ\|LkG1NkDPxE1?	NHvu[GpUSU6JRWK=
NB7	NYrQfoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXYNYdiUUN3ME2yOE4yQDhizszN	MoX0V2FPT0WU
HCC1569	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDXW\|FKSzVyPUK0MlYyOjVizszN	NXvuRXY4W0GQR1XS
MEL-JUSO	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLGTWM2OD1{ND62PVA5KM7:TR?=	M2rufXNCVkeHUh?=
MDA-MB-175-VII	NXy0SolZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTPcGFrUUN3ME2yOU4zPTF5IN88US=>	Mn;CV2FPT0WU
HCC1419	NXvFXFJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ3Lk[wNFMh\|ryP	MlT3V2FPT0WU
Ca9-22	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jMS2lEPTB;MkWuOlQ{OiEQvF2=	Mn2yV2FPT0WU
KGN	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTJ3Lke1OFch\|ryP	M4HXb3NCVkeHUh?=
LB373-MEL-D	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon4TWM2OD1{Nj6xPVM5KM7:TR?=	MUPTRW5ITVJ?
NCI-H1755	M4\ldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTSUHo4UUN3ME2yOk45QDRzIN88US=>	MUHTRW5ITVJ?
D-423MG	NXm4b41XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjrPGNEUUN3ME2yO{4xPzF3IN88US=>	MnjTV2FPT0WU
DK-MG	NVXnTlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;MOXJKSzVyPUK4Mlc5PDZizszN	M13wfnNCVkeHUh?=
NCI-H1623	NUPR[ZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHWZnJkUUN3ME2yPE45OzR{IN88US=>	Ml7CV2FPT0WU
KU-19-19	M17VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jLWmlEPTB;MkiuPVk2KM7:TR?=	M4PkfXNCVkeHUh?=
C-33-A	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j0XWlEPTB;MkmuNlE6QCEQvF2=	Mnv3V2FPT0WU
SCC-4	NH;0WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrKXW5KSzVyPUOwMlM{PTRizszN	MnjYV2FPT0WU
MG-63	NXTW[451T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTNyLkW5PVQh\|ryP	NXnqRmFCW0GQR1XS
LNCaP-Clone-FGC	NV;1VWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTNzLkS5NlEh\|ryP	Ml\aV2FPT0WU
CAPAN-1	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYqxco5yUUN3ME2zNU42Ojh4IN88US=>	M{fRbnNCVkeHUh?=
GI-ME-N	NWX0VGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\uV2lEPTB;M{GuOVM2OyEQvF2=	NGH6XmNUSU6JRWK=
RERF-LC-MS	NHPFSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\nWmlEPTB;M{KuOlc1PyEQvF2=	NEezSVFUSU6JRWK=
KLE	M3LrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXxN4pKSzVyPUOzMlQ{OzRizszN	M2KyTnNCVkeHUh?=
KNS-81-FD	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1T4SmlEPTB;M{OuOVAxQCEQvF2=	NIXyWINUSU6JRWK=
DOK	NFj3dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jobGlEPTB;M{SuOlYyOiEQvF2=	NVrQRlJUW0GQR1XS
ACHN	NV\HcXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfpOFFqUUN3ME2zOU4yPTh6IN88US=>	NWG1NlVjW0GQR1XS
KYSE-520	M3n1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfhVHJKSzVyPUO1MlI{PjFizszN	MYjTRW5ITVJ?
SBC-5	NULZPIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\BXoN3UUN3ME2zOU42OTF4IN88US=>	MXTTRW5ITVJ?
NCI-H28	NHnySpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PmfmlEPTB;M{WuOlY6PSEQvF2=	NXXvNFlGW0GQR1XS
ES7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;rU3BsUUN3ME2zOk4zOjR7IN88US=>	MkjpV2FPT0WU
A172	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnGTWM2OD1\|Nj60NVg4KM7:TR?=	NGXuOYFUSU6JRWK=
UM-UC-3	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTN5Lki3OFYh\|ryP	M2T2THNCVkeHUh?=
LXF-289	NWrGfYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPjTWM2OD1\|OD6wNFQ4KM7:TR?=	NUHyNWVlW0GQR1XS
KP-4	NGTRcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTN6LkS3N\|kh\|ryP	MmfnV2FPT0WU
TE-1	NFTJR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi0RZFrUUN3ME2zPU43PTh7IN88US=>	MV\TRW5ITVJ?
G-402	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLre4JUUUN3ME20NE4xPjFizszN	NGL1fodUSU6JRWK=
786-0	NFjY[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHnTWM2OD12MD65NFk3KM7:TR?=	Mle3V2FPT0WU
K5	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELKZW9KSzVyPUSxMlM3QDZizszN	NGO0fVNUSU6JRWK=
SK-N-DZ	M3fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTRzLkO4NlMh\|ryP	MlvVV2FPT0WU
OVCAR-4	NYDEblZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jFTmlEPTB;NEGuO\|U3QCEQvF2=	M2TrS3NCVkeHUh?=
T84	M1jUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXIdFlKSzVyPUSyMlEzPjNizszN	Mnv1V2FPT0WU
GCIY	NULRXGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR\|LkC4NFMh\|ryP	M1PTfHNCVkeHUh?=
BB49-HNC	NFj3UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HRSmlEPTB;NEOuN\|M1QCEQvF2=	MljMV2FPT0WU
SNU-C2B	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXKTWM2OD12Mz62OFM3KM7:TR?=	MnfhV2FPT0WU
TE-6	NX3TbZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4i3VWlEPTB;NEOuPFg6PCEQvF2=	MlzJV2FPT0WU
23132-87	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTjcFFTUUN3ME20OE4zQTd6IN88US=>	M1HheHNCVkeHUh?=
DMS-53	M1G4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTR2LkOzPFQh\|ryP	NHjVfGNUSU6JRWK=
ONS-76	M4C3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT4NIt1UUN3ME20OE44PjZzIN88US=>	NF3seHlUSU6JRWK=
DMS-273	M3zpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHL2NW1KSzVyPUS0Mlk1OyEQvF2=	NXLDO2VWW0GQR1XS
COLO-824	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[3c5hKSzVyPUS1Mlg4PzVizszN	MXvTRW5ITVJ?
DMS-114	NXS2TnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\DNXpKSzVyPUS1Mlg6OjdizszN	NYrreoo4W0GQR1XS
YKG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTRTWM2OD12Nj6wN\|U2KM7:TR?=	NFHQfXdUSU6JRWK=
RH-18	NVq1enFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTJNJJKSzVyPUS2MlM4OzNizszN	NUi4fZYyW0GQR1XS
NCI-H1355	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGTGRKSzVyPUS2MlYyQCEQvF2=	NIHuN2hUSU6JRWK=
NCI-H2170	NITVPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfSRYJKSzVyPUS3Mlc2QDRizszN	M{nXb3NCVkeHUh?=
OC-314	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nlWWlEPTB;NEeuPFQ4QCEQvF2=	MUjTRW5ITVJ?
NCI-H2030	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnxUHdKSzVyPUS3Mlg6ODZizszN	MmXWV2FPT0WU
22RV1	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzpV4F7UUN3ME20O{46ODF3IN88US=>	MkXsV2FPT0WU
G-401	NF\oOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTR6LkS0NVUh\|ryP	MlHaV2FPT0WU
YAPC	M2Txb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTR7LkiwO\|Mh\|ryP	M3\qS3NCVkeHUh?=
SW1573	M1zOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTVyLkK0N\|Uh\|ryP	NX[zbHBtW0GQR1XS
COLO-792	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHMTWM2OD13MD62NlM4KM7:TR?=	M3vib3NCVkeHUh?=
KNS-62	NXH0WlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvRbIRKSzVyPUWwMlc2ODhizszN	NVm0NGp6W0GQR1XS
NB5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnQTW9WUUN3ME21NU41PTB7IN88US=>	NFP6UXZUSU6JRWK=
CP66-MEL	NUKxXWtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn2UHdKSzVyPUWxMlY1ODhizszN	MYjTRW5ITVJ?
CaR-1	M1\ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;NPGRKSzVyPUWyMlA3ODZizszN	NF;3UZpUSU6JRWK=
CAL-54	M2DYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPRPIZKSzVyPUWyMlEyODJizszN	MoLwV2FPT0WU
8305C	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTV{LkOxOUDPxE1?	NYTxdZZoW0GQR1XS
Calu-3	NXX6OpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTV{LkO3N\|Mh\|ryP	M1;1NnNCVkeHUh?=
AU565	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPZTWM2OD13Mj61OVA6KM7:TR?=	MVXTRW5ITVJ?
CW-2	NYDucXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTWTWM2OD13Mj64OlU1KM7:TR?=	NEf5SXhUSU6JRWK=
BEN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTV\|Lke4OlIh\|ryP	NVXnPYRxW0GQR1XS
NCI-H1975	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWKyZZkyUUN3ME21N{45QTZ4IN88US=>	MoLxV2FPT0WU
HCT-116	NXLtbJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrXTWM2OD13ND6wN\|I4KM7:TR?=	M3TrNHNCVkeHUh?=
SH-4	MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDxR3o{UUN3ME21OE4yOzhizszN	NIHDTlJUSU6JRWK=
NCI-H1693	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTV2LkKxNFMh\|ryP	MnviV2FPT0WU
BPH-1	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTV3LkK4PVIh\|ryP	MojzV2FPT0WU
CAMA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfmNWZsUUN3ME21OU45OTF4IN88US=>	NIj5WY9USU6JRWK=
A388	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTV4LkC5PFUh\|ryP	NWnkPGRxW0GQR1XS
C2BBe1	NUXu[otlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLNepBLUUN3ME21Ok4zPjN2IN88US=>	MV7TRW5ITVJ?
GAMG	NWLsfXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj0RnJKSzVyPUW2MlU6PTVizszN	M4fkSXNCVkeHUh?=
MKN28	M{LnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HQSGlEPTB;NU[uPFAyOyEQvF2=	M1jHNHNCVkeHUh?=
VA-ES-BJ	NUTQVmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O2NGlEPTB;NU[uPFc1PSEQvF2=	MXzTRW5ITVJ?
HuCCT1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX2TWM2OD13Nz6wOFkzKM7:TR?=	MkXWV2FPT0WU
BFTC-905	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmT0TWM2OD13Nz6yPFk5KM7:TR?=	MmCzV2FPT0WU
LS-123	M3zoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7iTWM2OD13Nz61OlY5KM7:TR?=	MVzTRW5ITVJ?
LB996-RCC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe0d4tKSzVyPUW4MlAzQDdizszN	NYXwXHVxW0GQR1XS
NCI-H1048	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTV6LkKxPFgh\|ryP	MV7TRW5ITVJ?
COR-L105	NVLyZlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzrTWM2OD13OD63N\|M4KM7:TR?=	MXLTRW5ITVJ?
OVCAR-8	M3y5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTV7LkG3NVYh\|ryP	NUXa[mNRW0GQR1XS
SK-N-FI	NEn0WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[xNXFKSzVyPUW5MlMzODdizszN	NEHZV3VUSU6JRWK=
MES-SA	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nlPWlEPTB;NUmuOFUxQSEQvF2=	MYjTRW5ITVJ?
SCC-9	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEeyT4FKSzVyPUW5MlQ4PTNizszN	MkXtV2FPT0WU
EFO-27	NXzTRZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWKzdIpjUUN3ME21PU46PDNizszN	NFjJTo9USU6JRWK=
GT3TKB	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkL6TWM2OD14MD62NFQ5KM7:TR?=	M{fzWnNCVkeHUh?=
HCC38	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DHNmlEPTB;NkGuOFM4QSEQvF2=	M3\tPHNCVkeHUh?=
MLMA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXsO\|hKSzVyPU[xMlYyPjNizszN	NWXZWGdCW0GQR1XS
D-566MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fUNmlEPTB;NkOuOVIzPCEQvF2=	M3;ROnNCVkeHUh?=
SF295	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPMb45KSzVyPU[zMlY3PTVizszN	MnLaV2FPT0WU
ES4	NX;sTFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTZ2LkS3NVkh\|ryP	NV\3UohnW0GQR1XS
CAKI-1	NGDKOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTQU2tKSzVyPU[0MlU4OjFizszN	Mn;0V2FPT0WU
OAW-28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV25dWxEUUN3ME22OE46PjR5IN88US=>	MXfTRW5ITVJ?
NCI-H460	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTZ3LkC4PVch\|ryP	NWrpUXUyW0GQR1XS
JAR	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonLTWM2OD14NT61OVE3KM7:TR?=	M{K1TnNCVkeHUh?=
SNU-449	NF3DR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH4N5lKSzVyPU[1Mlc3OTZizszN	M2TkR3NCVkeHUh?=
D-392MG	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1GxR2lEPTB;NkWuPVQ{PCEQvF2=	MYDTRW5ITVJ?
EW-22	NEXMNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrrTJZKSzVyPU[2MlM6PSEQvF2=	MkfZV2FPT0WU
GCT	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmCyTWM2OD14Nz6wOFQ{KM7:TR?=	MYrTRW5ITVJ?
NOS-1	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\iTWM2OD14Nz62PFY4KM7:TR?=	M{HyOXNCVkeHUh?=
RH-1	M2fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTZ6LkW1OVkh\|ryP	MV3TRW5ITVJ?
HuH-7	NFLZSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLGTWM2OD14OT6xNFAzKM7:TR?=	NHzIO5ZUSU6JRWK=
NUGC-3	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnkNGNUUUN3ME23NE46PjR2IN88US=>	MljJV2FPT0WU
IST-SL1	M1fLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvYTotKSzVyPUexMlI{OjRizszN	NVLpdmRqW0GQR1XS
SHP-77	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XPc2lEPTB;N{KuNVE6KM7:TR?=	NIe4SZdUSU6JRWK=
SW1116	NFfVXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW1eFM3UUN3ME23Nk4yPDB5IN88US=>	M3Hr[nNCVkeHUh?=
LK-2	NVHGZVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvFTWM2OD15Mj64OlEzKM7:TR?=	NIDOeodUSU6JRWK=
U-2-OS	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTd\|LkG4Nlgh\|ryP	NGPvb3dUSU6JRWK=
KYSE-150	NXOwUXJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\SNHdKSzVyPUezMlYyOThizszN	NFHSNlVUSU6JRWK=
U251	NYW2OVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnOwTWM2OD15Mz64NVY5KM7:TR?=	NF32cIpUSU6JRWK=
HT-1080	NGOz[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\YeWlEPTB;N{SuNlU4PCEQvF2=	MXHTRW5ITVJ?
NCI-H1437	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTSN\|Z5UUN3ME23OE43OzJ4IN88US=>	M1zYfXNCVkeHUh?=
HPAF-II	NYnzPGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfsNGxtUUN3ME23OE43PDF3IN88US=>	NEnTbmJUSU6JRWK=
Becker	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTd3LkGxNFUh\|ryP	MX;TRW5ITVJ?
PANC-10-05	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j3XmlEPTB;N{WuNlg3PSEQvF2=	MnvCV2FPT0WU
TYK-nu	NWixdlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;DbmlEPTB;N{WuN\|ExOiEQvF2=	M{mwbXNCVkeHUh?=
SKG-IIIa	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULvNmVYUUN3ME23OU4{OzRzIN88US=>	Mm\kV2FPT0WU
NCI-H1993	NIO3XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITwTIdKSzVyPUe1Mlc{QTdizszN	Mn\pV2FPT0WU
S-117	NFu5V\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonsTWM2OD15NT63OVUh\|ryP	NVXXN2lDW0GQR1XS
HuO9	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH0TWM2OD15Nj6wNFQ5KM7:TR?=	NXTBSFh4W0GQR1XS
CAL-51	M3vncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLucVZKSzVyPUe2MlExODZizszN	MljFV2FPT0WU
BT-20	M4f1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPvR2RNUUN3ME23Ok4zOTZ6IN88US=>	NYfzfVQ{W0GQR1XS
LB831-BLC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGK5SG1KSzVyPUe2MlMzOTdizszN	NUfBWWdHW0GQR1XS
LB1047-RCC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXrdWhKSzVyPUe2Mlc3OTlizszN	M3OwR3NCVkeHUh?=
ES8	NV;1OmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHkTWM2OD15OD6wNFc{KM7:TR?=	NX\HRoxjW0GQR1XS
UMC-11	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkKwTWM2OD15OD6wPFg1KM7:TR?=	NUHOVmx2W0GQR1XS
NCI-H226	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4e3TWlEPTB;N{iuNVMyPSEQvF2=	MWLTRW5ITVJ?
IGROV-1	M4TKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{OzNWlEPTB;N{iuOVU2KM7:TR?=	M3HyS3NCVkeHUh?=
BHY	NEXRRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7pOIVKSzVyPUe5MlU6PiEQvF2=	MYjTRW5ITVJ?
MKN45	M120RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Hzc2lEPTB;OECuN\|E4PCEQvF2=	M{fiNnNCVkeHUh?=
IA-LM	NUTlS2p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX0TWM2OD16MD6zOVEyKM7:TR?=	Ml60V2FPT0WU
WM-115	NXXJeFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrlW4V2UUN3ME24NU41OTF2IN88US=>	MVfTRW5ITVJ?
VMRC-RCZ	NYDSW3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC4TWM2OD16MT60OFI2KM7:TR?=	M3z3TnNCVkeHUh?=
NCI-H2291	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\NVoVvUUN3ME24NU43QDR{IN88US=>	MoXzV2FPT0WU
MCF7	NFLtO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LZfGlEPTB;OEOuNlg6PyEQvF2=	M{O5NnNCVkeHUh?=
639-V	NGW5[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHqTWM2OD16ND62NVI6KM7:TR?=	NHjjZ4tUSU6JRWK=
RT4	M3jVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXIT5NKSzVyPUi1MlI1ODNizszN	MUTTRW5ITVJ?
NCI-H2405	NILpW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzDTWM2OD16NT6yPVk4KM7:TR?=	MWTTRW5ITVJ?
CAL-33	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnhWnBKSzVyPUi1MlY{OTVizszN	Ml\nV2FPT0WU
BT-549	M{LUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XURWlEPTB;OEWuPVM5OiEQvF2=	NFXvOlRUSU6JRWK=
HT-1197	NYnxUWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HtVWlEPTB;OEiuNVA4PyEQvF2=	NH72W5hUSU6JRWK=
G-361	M4DRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfWTWM2OD16OD6xOFc1KM7:TR?=	MmTWV2FPT0WU
LS-411N	NVHOdm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\Gd2lEPTB;OEmuN\|M5QCEQvF2=	NF3FU29USU6JRWK=
HT-144	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXUTWM2OD16OT61PVkzKM7:TR?=	NUjac41DW0GQR1XS
DJM-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;qe3pKSzVyPUi5Mlg5PDVizszN	MX;TRW5ITVJ?
CAL-12T	NUTxSIJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7TUoFsUUN3ME25NE44QDl3IN88US=>	MXXTRW5ITVJ?
MKN7	M3PmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX24cZU1UUN3ME25NU4{PTVzIN88US=>	Ml;EV2FPT0WU
HuP-T3	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjWcnJyUUN3ME25Ok4yODB2IN88US=>	MoryV2FPT0WU
SK-MG-1	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr5[WZwUUN3ME25Ok4yOzR6IN88US=>	M{PVWHNCVkeHUh?=
NCI-H2347	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTl6LkGwOFIh\|ryP	NHLUWYRUSU6JRWK=
SW872	NIexUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjGTWM2OD1zMECuOFU3KM7:TR?=	MoTpV2FPT0WU
COLO-829	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7JXZBKSzVyPUGwNE42PTNizszN	MVnTRW5ITVJ?
MC-IXC	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTGT3l4UUN3ME2xNFAvPjF3IN88US=>	MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 10 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 10 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)